Research Laboratory of Emerging Parasitic Diseases, Tunis, Tunisia.
Am J Trop Med Hyg. 2009 Dec;81(6):1004-6. doi: 10.4269/ajtmh.2009.09-0285.
Forty-two patients with visceral leishmaniasis in Tunisia were treated with meglumine antimoniate and followed-up for clinical improvement and blood parasite load determined by quantitative real-time polymerase chain reaction (PCR). Parasite loads before treatment ranged from 27 to 5.3 x 10(7) parasites/mL. At the end of treatment, parasite load decreased significantly in 39 cured patients (P < 0.001). The decrease in parasite load after treatment was greater than 99% for 34 patients and PCR results became negative in 23 of them. Two patients without clinical improvement showed no or slight decreases in parasite load (209 versus 202 parasites/mL and 1,765 versus 146 parasites/mL). One patient showed had a relapse seven months after showing a good response to treatment. His parasitemia remained high despite a sharp decrease (5.2 x 10(5) versus 5.9 x 10(3) parasites/mL).
突尼斯的 42 例内脏利什曼病患者接受了葡甲胺锑治疗,并进行了临床改善和血液寄生虫载量的随访,寄生虫载量通过定量实时聚合酶链反应 (PCR) 确定。治疗前寄生虫载量范围为 27 至 5.3 x 10(7) 个寄生虫/毫升。在治疗结束时,39 例治愈患者的寄生虫载量显著下降(P < 0.001)。在 34 名患者中,治疗后寄生虫载量下降超过 99%,其中 23 名患者的 PCR 结果变为阴性。两名无临床改善的患者寄生虫载量无明显或轻微下降(209 与 202 个寄生虫/毫升和 1,765 与 146 个寄生虫/毫升)。一名患者在对治疗有良好反应七个月后复发。尽管寄生虫载量急剧下降(5.2 x 10(5) 与 5.9 x 10(3) 个寄生虫/毫升),但其仍保持较高水平。